The findings clarify the role of ACTL6A in metabolic reprogramming in ovarian cancer and propose a potential molecular mechanism for targeting ACTL6A to inhibit glycolysis and exert anti-tumor activity. This evidence concerns the gene ACTL6A and neoplasm.